It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.
We have taken over 70 companies to a successful exit since setting up the Novartis Venture Fund in 1996 – that is three on average per year. These exits have primarily resulted in IPOs and M&As, with several drugs receiving FDA approval.
The NVF team is made up of people with expert backgrounds in science and business development, as well as vast experience bringing new therapeutics and pharmaceutical products to market. Our focus is developing novel therapeutics and platforms that address unmet needs and deliver clinical impact.
We like to employ a very collaborative, hands-on style of investment that sees us work closely with the leadership and management of each company as a member of the board. We believe that analyzing the depth of your team is as important as studying the science behind your product.
Open to investing in life science companies at any stage of growth, our primary focus is on seed and Series A stage investment. What we look for principally are products under development that address an unmet clinical need. Once this condition is met, we review all non-confidential information available about the company and conduct an in-depth examination of its people, technology, data, finances, and exit ambitions.
After that, the evaluation process begins with a confidential discussion with the company. This is then followed by a thorough due diligence process. This meticulous approach enables us to make informed investment decisions and aligns with our commitment to support innovative solutions that meet critical clinical needs.
Learn more about our life science investmentsthat resulted in IPOs.
See which companies in our portfolio have exited by way of M&A.